Page last updated: 2024-10-15

azilsartan

Description

azilsartan: an angiotensin type 1 receptor blocker; receptor blocker [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

azilsartan : A benzimidazolecarboxylic acid that is benzimidazole-7-carboxylic acid substituted at position 2 by a methoxy group and at position 1 by a 2'-[(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl group. Used (as the prodrug, azilsartan medoxomil) for treatment of hypertension. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135415867
CHEMBL ID57242
CHEBI ID68850
SCHEMBL ID167538
MeSH IDM0511612

Synonyms (85)

Synonym
bdbm50055441
2-ethoxy-3-[2''-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1h-benzo[d]imidazole-7-carboxylic acid
tak-536
azilsartan
chebi:68850 ,
CHEMBL57242 ,
L001451
D08864
azilsartan (jan/usan/inn)
147403-03-0
azilva (tn)
FT-0662457
AKOS007930882
1h-benzimidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-
BCP9000002
CS-1396
1h-benzimidazole-7-carboxylic acid, 1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol- 3-yl)(1,1'-biphenyl)-4-yl)methyl)-2-ethoxy-
2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-biphenyl-4-yl)methyl)-1h-benzimidazole-7-carboxylic acid
azilsartan [usan:inn]
f9nux55p23 ,
tak 536
unii-f9nux55p23
2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)- 1h-benzimidazole-7-carboxylic acid
hsdb 8208
BCP0726000135
2-ethoxy-1-[[2'-(4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid
1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1h-benzimidazole-7-carboxylic acid
azilsartan [inn]
azilsartan [jan]
azilsartan [who-dd]
azilsartan [usan]
azilsartan [mart.]
azilsartan [mi]
azilsartan [vandf]
2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1h-benzimidazole-7-carboxylic acid
AM84439
2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid
S3046
CX1016
2-ethoxy-3-[2'-(5-oxo-4,5-dihydro-[1,2,4]oxadiazol-3-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid
2-ethoxy-3-[[4-[2-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
gtpl6901
tak536
HY-14914
SCHEMBL167538
KGSXMPPBFPAXLY-UHFFFAOYSA-N
2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl4-yl]methyl]benzimidazole-7-carboxylic acid
2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid
AC-25912
AKOS024458220
AB01566867_01
DTXSID70163712 ,
mfcd20278186
KS-5381
HMS3651J16
azilsartan, >=98% (hplc)
NCGC00386206-04
SW219493-1
1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) [1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1h-benzimidazole-7-carboxylic acid
FT-0662458
BCP03826
1794817-45-0
azilsartan (tak-536)
Q27074832
SB20804
AMY4360
HMS3747I09
CCG-269296
NCGC00386206-03
2-ethoxy-3-[[4-[2-(5-oxo-4h-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
azilsartan free acid
WDC59945
BA164233
azilsartan- bio-x
azilva
dtxcid1086203
azilsartan (mart.)
2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1h-benzimidazole-7-carboxylic acid
2-ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-1,3-benzodiazole-7-carboxylic acid
EN300-6482027
mfcd00916395
SY025841
2-ethoxy-1-[[2 inverted exclamation mark -(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid
Z1575099375

Research Excerpts

Overview

Azilsartan (AZL) is an angiotensin II receptor antagonist, which is mainly used for the treatment of hypertension. It is an FDA-approved selective AT1R antagonist that is used to treat hypertension.

ExcerptReference
"Azilsartan is an angiotensin II receptor blocker indicated for the treatment of adult hypertension. "( Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study.
Enya, K; Ito, S; Nishiyama, Y; Sugiura, K, 2022
)
"Azilsartan (AZL) is an angiotensin II receptor antagonist, which is mainly used for the treatment of hypertension. "( Azilsartan-nicotinamide cocrystal: Preparation, characterization and in vitro / vivo evaluation.
Geng, X; Jin, T; Xiao, Y; Zhu, X, 2022
)
"Azilsartan is an FDA-approved selective AT1R antagonist that is used to treat hypertension."( Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesis
Fan, Z; Kanou, K; Kitaura, H; Lin, A; Ma, J; Marahleh, A; Miura, M; Mizoguchi, I; Narita, K; Noguchi, T; Ohori, F; Ren, J, 2023
)
"Azilsartan is an FDA-approved selective AT1R antagonist that is used to treat hypertension."( Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesis
Fan, Z; Kanou, K; Kitaura, H; Lin, A; Ma, J; Marahleh, A; Miura, M; Mizoguchi, I; Narita, K; Noguchi, T; Ohori, F; Ren, J, 2023
)
"Azilsartan is an effective blood pressure lowering drug and well tolerated and was non- inferior to telmisartan in its safety and efficacy."( Evaluation of the Efficacy and Safety of Azilsartan in Adult Patients with Essential Hypertension: A Randomized, Phase-III Clinical Study in India.
Agarwal, M; Chary, S; Naik K, S; Reddy Bandi, M; Reddy, VK; Sinha, S; Talluri, L; Thakur, P, 2021
)
"Azilsartan is a strong antihypertensive ARB, but its antiproteinuric effects are not well understood."( Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial.
Eriguchi, M; Fujisaki, K; Kitazono, T; Nakano, T; Suehiro, T; Tanaka, S; Torisu, K; Tsuchimoto, A; Tsujikawa, H; Tsuruya, K; Yamada, S; Yoshida, H, 2021
)
"Azilsartan is a potent agent for the treatment of hypertension as the antagonist of the angiotensin II receptor."( Azilsartan ameliorates ox-LDL-induced endothelial dysfunction via promoting the expression of KLF2.
Chen, F; Li, W; Luo, J; Wang, C; Xiao, S; Zeng, K; Zhang, D, 2021
)
"Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. "( Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.
Enya, K; Ikeda, Y; Rakugi, H; Sugiura, K, 2012
)
"Azilsartan is a new ARB with the specific and potent angiotensin II receptor binding-inhibitory effect and more continuous angiotensin II antagonistic and antihypertensive actions in pre-clinical studies compared with other ARBs. "( [Azilsartan: a new angiotensin receptor blocker].
Enya, K; Rakugi, H, 2012
)

Effects

ExcerptReference
"Azilsartan medoxomil has a potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors, which may play a role in its superior blood pressure (BP) -lowering efficacy compared with other drugs, including ramipril, candesartan, valsartan or olmesartan, without an increase of side effects. "( Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios, V; Escobar, C, 2013
)
"Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing for years."( Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
Bleske, BE; Dorsch, MP; Shuster, JE, 2012
)

Treatment

Azilsartan treatment prevented AGEs-induced inflammatory response and degradation of aggrecan through inhibition of Sox4. Treatment with azilartan or olmesartan (1 or 5 mg kg(-1) per day) significantly decreased systolic and diastolic blood pressure.

ExcerptReference
"Azilsartan-treated calvariae exhibited significantly lower bone resorption and osteoclastogenesis than those treated with LPS alone. "( Azilsartan inhibits inflammation-triggered bone resorption and osteoclastogenesis
Fan, Z; Kanou, K; Kitaura, H; Lin, A; Ma, J; Marahleh, A; Miura, M; Mizoguchi, I; Narita, K; Noguchi, T; Ohori, F; Ren, J, 2023
)
"Azilsartan treatment prevented AGEs-induced inflammatory response and degradation of aggrecan through inhibition of Sox4."( Azilsartan prevented AGE-induced inflammatory response and degradation of aggrecan in human chondrocytes through inhibition of Sox4.
He, C; He, M; Lei, J; Li, J; Wang, W; Xu, L, 2021
)
"Azilsartan treatment ameliorated cardiac hypertrophy/fibrosis significantly in AAC rats. "( Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway.
Cai, SA; Hou, N; Huang, Y; Li, LR; Liu, XW; Luo, CF; Pan, WB; Shi, YY; Yuan, WC; Zhan, HX; Zhao, GJ, 2021
)
"Pre-treatment with azilsartan (2 and 4 mg/kg; p.o.) or coenzyme Q10 (20 and 40 mg/kg; p.o.) starting 7 days prior to BCCAO till the end of reperfusion was done."( Neuroprotective potential of azilsartan against cerebral ischemic injury: Possible involvement of mitochondrial mechanisms.
Dhull, DK; Gupta, V; Joshi, J; Kaur, S; Kumar, A, 2020
)
"The "Treatment with Azilsartan Compared to ACE-Inhibitors in Anti-Hypertensive Therapy" (EARLY) registry is a prospective, observational, national, multicenter registry with a follow-up of up to 12 months. "( EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry.
Baumgart, P; Bramlage, P; Buhck, H; Gitt, AK; Mahfoud, F; Potthoff, SA; Schmieder, RE; Schneider, S; Senges, J, 2013
)
"Treatment with azilsartan or olmesartan (1 or 5 mg kg(-1) per day) significantly decreased systolic and diastolic blood pressure, and the blood pressure-lowering effect of azilsartan was more marked than that of olmesartan."( Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
Bai, HY; Chisaka, T; Horiuchi, M; Iwanami, J; Kanno, H; Min, LJ; Mogi, M; Nakaoka, H; Ohshima, K; Tsukuda, K; Wang, XL, 2014
)

Toxicity

ExcerptReference
" Treatment with 10-mg azilsartan was similar to 8-mg candesartan cilexetil in its association with rare adverse events."( Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
Arai, A; Kaneto, H; Katakami, N; Kusuda, Y; Matsuoka, TA; Shimomura, I; Shindo, M; Shiraiwa, T; Takahara, M, 2014
)
"Most adverse events (AEs) were mild or moderate in intensity, and no deaths or treatment-related serious AEs were reported."( A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.
Nishiyama, Y; Rakugi, H; Sano, Y; Shimizu, K; Umeda, Y, 2018
)
" Headache and dizziness were the most frequent treatmentrelated treatment-emergent adverse events."( Evaluation of the Efficacy and Safety of Azilsartan in Adult Patients with Essential Hypertension: A Randomized, Phase-III Clinical Study in India.
Agarwal, M; Chary, S; Naik K, S; Reddy Bandi, M; Reddy, VK; Sinha, S; Talluri, L; Thakur, P, 2021
)
" Most drug-related adverse events (AEs) were mild, with one patient (3."( Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study.
Enya, K; Ito, S; Nishiyama, Y; Sugiura, K, 2022
)

Pharmacokinetics

ExcerptReference
" The present study aimed to evaluate the safety and pharmacokinetic properties of AZL in healthy Chinese subjects."( Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects.
Chen, G; Chen, H; Cui, D; Ding, Y; Guo, Y; Jiao, Z; Li, C; Li, X; Liu, J; Shen, Z; Sheng, C; Wu, M; Zhang, H; Zhu, X, 2020
)

Bioavailability

ExcerptReference
" This might be ascribed to their improved bioavailability by increased lipophilicity."( Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
Imamiya, E; Inada, Y; Kohara, Y; Kubo, K; Naka, T; Wada, T, 1996
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
" And the pharmacokinetic results showed that AZL-NA cocrystal could significantly improve the bioavailability of AZL."( Azilsartan-nicotinamide cocrystal: Preparation, characterization and in vitro / vivo evaluation.
Geng, X; Jin, T; Xiao, Y; Zhu, X, 2022
)

Dosage Studied

The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ±-64 mg per day. The dosage of olmesartan and azilartan increased significantly and slightly for 16 weeks.

ExcerptReference
" The dosage of olmesartan and azilsartan increased significantly and slightly for 16 weeks (OL group: 20."( Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study).
Hanayama, Y; Kakio, Y; Okuyama, Y; Takeuchi, H; Uchida, HA; Umebayashi, R; Wada, J, 2017
)
" During single dosing of AZL, the pharmacokinetics of AZL exhibited a linear profile between dosage and area under the concentration-time curve."( Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects.
Chen, G; Chen, H; Cui, D; Ding, Y; Guo, Y; Jiao, Z; Li, C; Li, X; Liu, J; Shen, Z; Sheng, C; Wu, M; Zhang, H; Zhu, X, 2020
)
" The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ± 64 mg/day."( Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension.
Fukushima, H; Horio, T; Ishimitsu, T; Iwashima, Y; Rai, T, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
angiotensin receptor antagonistA hormone antagonist that blocks angiotensin receptors.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzimidazolecarboxylic acidA member of the class of benzimidazoles carrying a carboxy group at unspecified position.
1,2,4-oxadiazole
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1779666Agonist activity at human BLT2 overexpressed in CHO-K1 cells assessed as accumulation of inositol monophosphate measured after 90 mins by HTRF assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.
AID16032Bioavailability1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID181935Percent inhibition of AII (0.1 ug/kg iv) -induced pressor response at 7 hr after administration of test compounds (0.1 mg/kg po) in conscious male Sprague-Dawley rats.1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID39039Inhibition of specific binding of [125I]angiotensin II (0.2 nM) to angiotensin II receptor in bovine adrenal cortex1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID568788Binding affinity to angiotensin AT1 receptor in bovine adrenal cortex membranes2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID26605pka value was determined1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID23686Partition coefficient (logP)1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID568922Antihypertensive activity in po dosed conscious rat2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID181931Percent inhibition of angiotensin II (0.1 ug/kg iv) -induced pressor response 3h after administration of test compounds (1 mg/kg po) in conscious male Sprague-Dawley rats1996Journal of medicinal chemistry, Dec-20, Volume: 39, Issue:26
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres.
AID1346995Human AT1 receptor (Angiotensin receptors)2014Hypertension research : official journal of the Japanese Society of Hypertension, Sep, Volume: 37, Issue:9
Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
AID1346995Human AT1 receptor (Angiotensin receptors)2014Clinical therapeutics, May, Volume: 36, Issue:5
Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (119)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (0.84)18.2507
2000's1 (0.84)29.6817
2010's86 (72.27)24.3611
2020's31 (26.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (20.16%)5.53%
Reviews16 (12.90%)6.00%
Case Studies5 (4.03%)4.05%
Observational4 (3.23%)0.25%
Other74 (59.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]